Victor L Villemagne

Summary

Affiliation: University of Melbourne
Country: Australia

Publications

  1. ncbi In vivo evaluation of a novel tau imaging tracer for Alzheimer's disease
    Victor L Villemagne
    Centre for PET, Austin Health, Melbourne, Australia
    Eur J Nucl Med Mol Imaging 41:816-26. 2014
  2. ncbi La lunga attesa: towards a molecular approach to neuroimaging and therapeutics in Alzheimer's disease
    V L Villemagne
    Department of Nuclear Medicine, Centre for PET, Austin Health Heidelberg, Vic, Australia Department of Pathology, The University of Melbourne VIC, Australia The Mental Health Research Institute of Victoria, Parkville VIC, Australia
    Neuroradiol J 19:453-74. 2006
  3. pmc In vivo TSPO imaging in patients with multiple sclerosis: a brain PET study with [18F]FEDAA1106
    Akihiro Takano
    Center for Psychiatric Research, Department of Clinical Neuroscience, Karolinska Institutet, Stockholm SE 171 77, Sweden
    EJNMMI Res 3:30. 2013
  4. ncbi Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study
    Victor L Villemagne
    Department of Nuclear Medicine and Centre for PET, Austin Health, Melbourne, VIC 3084, Australia
    Lancet Neurol 12:357-67. 2013
  5. ncbi Long night's journey into the day: amyloid-β imaging in Alzheimer's disease
    Victor L Villemagne
    Department of Nuclear Medicine and Centre for PET, Austin Health, Heidelberg, Vic, Australia
    J Alzheimers Dis 33:S349-59. 2013
  6. doi Comparison of 11C-PiB and 18F-florbetaben for Aβ imaging in ageing and Alzheimer's disease
    Victor L Villemagne
    Department of Nuclear Medicine and Centre for PET, Austin Health, 145 Studley Road, Heidelberg, VIC 3084, Australia
    Eur J Nucl Med Mol Imaging 39:983-9. 2012
  7. doi 11C-PiB PET studies in typical sporadic Creutzfeldt-Jakob disease
    V L Villemagne
    Department of Nuclear Medicine, Centre for PET, Austin Health, 145 Studley Road, Heidelberg, VIC 3084, Australia
    J Neurol Neurosurg Psychiatry 80:998-1001. 2009
  8. doi Amyloid imaging with (18)F-florbetaben in Alzheimer disease and other dementias
    Victor L Villemagne
    Department of Nuclear Medicine and Centre for PET, Austin Health, Heidelberg, Victoria, Australia
    J Nucl Med 52:1210-7. 2011
  9. doi High striatal amyloid beta-peptide deposition across different autosomal Alzheimer disease mutation types
    Victor L Villemagne
    Department of Nuclear Medicine, Centre for Positron Emission Tomography, Austin Health, Heidelberg, Australia
    Arch Neurol 66:1537-44. 2009
  10. doi 11C-PiB PET ABri imaging in Worster-Drought syndrome (familial British dementia): a case report
    Victor L Villemagne
    Mental Health Research Institute, University of Melbourne, Melbourne, Vic, Australia
    J Alzheimers Dis 19:423-8. 2010

Detail Information

Publications86

  1. ncbi In vivo evaluation of a novel tau imaging tracer for Alzheimer's disease
    Victor L Villemagne
    Centre for PET, Austin Health, Melbourne, Australia
    Eur J Nucl Med Mol Imaging 41:816-26. 2014
    ..A non-invasive method of determining brain tau burden in vivo would allow a better understanding of the pathophysiology of tauopathies. The purpose of the study was to evaluate (18)F-THK523 as a potential tau imaging tracer...
  2. ncbi La lunga attesa: towards a molecular approach to neuroimaging and therapeutics in Alzheimer's disease
    V L Villemagne
    Department of Nuclear Medicine, Centre for PET, Austin Health Heidelberg, Vic, Australia Department of Pathology, The University of Melbourne VIC, Australia The Mental Health Research Institute of Victoria, Parkville VIC, Australia
    Neuroradiol J 19:453-74. 2006
    ..ma dov'è / la lenta processione di stagioni / che fu un'alba infinita e senza strade, / dov'è la lunga attesa e qual è il nome / del vuoto che ci invade. - Eugenio Montale. ..
  3. pmc In vivo TSPO imaging in patients with multiple sclerosis: a brain PET study with [18F]FEDAA1106
    Akihiro Takano
    Center for Psychiatric Research, Department of Clinical Neuroscience, Karolinska Institutet, Stockholm SE 171 77, Sweden
    EJNMMI Res 3:30. 2013
    ..18F]FEDAA1106 is a recently developed PET radioligand for the in vivo quantification of TSPO. In the present study, we aimed at investigating the diagnostic usefulness of [18F]FEDAA1106 in patients with MS...
  4. ncbi Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study
    Victor L Villemagne
    Department of Nuclear Medicine and Centre for PET, Austin Health, Melbourne, VIC 3084, Australia
    Lancet Neurol 12:357-67. 2013
    ..We aimed to use longitudinal data to calculate the rates of amyloid β (Aβ) deposition, cerebral atrophy, and cognitive decline...
  5. ncbi Long night's journey into the day: amyloid-β imaging in Alzheimer's disease
    Victor L Villemagne
    Department of Nuclear Medicine and Centre for PET, Austin Health, Heidelberg, Vic, Australia
    J Alzheimers Dis 33:S349-59. 2013
    ....
  6. doi Comparison of 11C-PiB and 18F-florbetaben for Aβ imaging in ageing and Alzheimer's disease
    Victor L Villemagne
    Department of Nuclear Medicine and Centre for PET, Austin Health, 145 Studley Road, Heidelberg, VIC 3084, Australia
    Eur J Nucl Med Mol Imaging 39:983-9. 2012
    ..The purpose of this analysis was to compare data on cortical Aβ deposition in subjects who had undergone both (11)C-PiB (PiB) and (18)F-florbetaben (FBB) PET imaging...
  7. doi 11C-PiB PET studies in typical sporadic Creutzfeldt-Jakob disease
    V L Villemagne
    Department of Nuclear Medicine, Centre for PET, Austin Health, 145 Studley Road, Heidelberg, VIC 3084, Australia
    J Neurol Neurosurg Psychiatry 80:998-1001. 2009
    ..The purpose of this study was to explore the premortem diagnostic utility of (11)C-PiB PET in sporadic Creutzfeldt-Jakob disease (CJD)...
  8. doi Amyloid imaging with (18)F-florbetaben in Alzheimer disease and other dementias
    Victor L Villemagne
    Department of Nuclear Medicine and Centre for PET, Austin Health, Heidelberg, Victoria, Australia
    J Nucl Med 52:1210-7. 2011
    ....
  9. doi High striatal amyloid beta-peptide deposition across different autosomal Alzheimer disease mutation types
    Victor L Villemagne
    Department of Nuclear Medicine, Centre for Positron Emission Tomography, Austin Health, Heidelberg, Australia
    Arch Neurol 66:1537-44. 2009
    ..Mutations in the amyloid precursor protein (APP), presenilin 1 (PSEN1), and presenilin 2 (PSEN2) genes lead to increased Abeta levels before symptoms arise...
  10. doi 11C-PiB PET ABri imaging in Worster-Drought syndrome (familial British dementia): a case report
    Victor L Villemagne
    Mental Health Research Institute, University of Melbourne, Melbourne, Vic, Australia
    J Alzheimers Dis 19:423-8. 2010
    ..We speculate that the sparsity of ABri plaques in the neocortex together with its high deposition in the cerebellum, might explain the observed pattern of 11C-PiB retention...
  11. ncbi In vivo assessment of vesicular monoamine transporter type 2 in dementia with lewy bodies and Alzheimer disease
    Victor L Villemagne
    Department of Nuclear Medicine, Centre for Positron Emission Tomography, Austin Hospital, Austin Health, Heidelber, Australia
    Arch Neurol 68:905-12. 2011
    ....
  12. doi Amyloid imaging
    Victor L Villemagne
    Department of Nuclear Medicine and Centre for PET, Austin Health, Victoria, Australia
    Int Psychogeriatr 23:S41-9. 2011
    ..Further longitudinal observations, coupled with different disease-specific tracers and biomarkers, are required to confirm this hypothesis and further elucidate the precise role of Aβ deposition in the course of AD...
  13. pmc Longitudinal assessment of Aβ and cognition in aging and Alzheimer disease
    Victor L Villemagne
    Department of Nuclear Medicine and Centre for PET, Austin Health, Heidelberg, Australia
    Ann Neurol 69:181-92. 2011
    ..Assess Aβ deposition longitudinally and explore its relationship with cognition and disease progression...
  14. doi Quantitative approaches to amyloid imaging
    Victor L Villemagne
    Department of Nuclear Medicine, Centre for PET, Austin Health, Heidelberg, VIC 3084, Australia
    Methods Mol Biol 680:201-25. 2011
    ..With the availability of novel amyloid imaging agents radiolabeled with either (11)C (half-life 20 min) or (18)F (half-life 110 min), a description of different image acquisition approaches is provided...
  15. ncbi The ART of loss: Abeta imaging in the evaluation of Alzheimer's disease and other dementias
    Victor L Villemagne
    Department of Nuclear Medicine, Centre for PET, Austin Health, 145 Studley Road, Heidelberg, Victoria 3084, Australia
    Mol Neurobiol 38:1-15. 2008
    ..Further longitudinal observations are required to confirm this hypothesis and to better elucidate the role of Abeta deposition in the course of Alzheimer's disease...
  16. ncbi Abeta deposits in older non-demented individuals with cognitive decline are indicative of preclinical Alzheimer's disease
    V L Villemagne
    Department of Nuclear Medicine, Centre for PET, Austin Health, 145 Studley Road, Heidelberg, VIC 3084, Australia
    Neuropsychologia 46:1688-97. 2008
    ..These observations suggest that neither memory decline nor Abeta deposition are part of normal ageing and likely represent preclinical AD. Further longitudinal observations are required to confirm this hypothesis...
  17. ncbi Predicting Alzheimer disease with β-amyloid imaging: results from the Australian imaging, biomarkers, and lifestyle study of ageing
    Christopher C Rowe
    Austin Health, Department of Nuclear Medicine and Centre for Positron Emission Tomography, Heidelberg, Victoria, Australia
    Ann Neurol 74:905-13. 2013
    ..We aimed to determine the prognostic value of β-amyloid imaging, alone and in combination with memory performance, hippocampal atrophy, and apolipoprotein E ε4 status in nondemented, older individuals...
  18. ncbi Decline in cognitive function over 18 months in healthy older adults with high amyloid-β
    Kathryn A Ellis
    Mental Health Research Institute, The University of Melbourne, Parkville, Vic, Australia
    J Alzheimers Dis 34:861-71. 2013
    ....
  19. ncbi Effect of amyloid on memory and non-memory decline from preclinical to clinical Alzheimer's disease
    Yen Ying Lim
    1 The Florey Institute of Neuroscience and Mental Health, Parkville, Victoria, Australia
    Brain 137:221-31. 2014
    ..Further, these results suggest that grouping amyloid data into at least two categories of abnormality may be useful in determining the disease risk level in non-demented individuals. ..
  20. doi BDNF Val66Met, Aβ amyloid, and cognitive decline in preclinical Alzheimer's disease
    Yen Ying Lim
    Mental Health Research Institute, The University of Melbourne, Parkville, Victoria, Australia
    Neurobiol Aging 34:2457-64. 2013
    ..High Aβ levels coupled with Met carriage may be useful prognostic markers of accelerated cognitive decline and hippocampal degeneration in individuals in the preclinical stage of AD. ..
  21. ncbi Differential diagnosis in Alzheimer's disease and dementia with Lewy bodies via VMAT2 and amyloid imaging
    Victor L Villemagne
    Mental Health Research Institute, University of Melbourne, Melbourne, Vic, Australia
    Neurodegener Dis 10:161-5. 2012
    ..The noninvasive evaluation of nigrostriatal dopaminergic integrity by PET can provide useful information for the differential diagnosis between dementia with Lewy bodies (DLB) and Alzheimer's disease (AD)...
  22. doi Aβ amyloid, cognition, and APOE genotype in healthy older adults
    Yen Ying Lim
    Department of Psychiatry, University of Melbourne, Parkville, Australia
    Alzheimers Dement 9:538-45. 2013
    ..Further, when demographic variables were controlled, the influence of APOE ε4 on the relationship between cerebral Aβ and cognition dissipated...
  23. doi Cognition and beta-amyloid in preclinical Alzheimer's disease: data from the AIBL study
    Kerryn E Pike
    Department of Nuclear Medicine, Centre for PET, Austin Health, Heidelberg, Vic, Australia
    Neuropsychologia 49:2384-90. 2011
    ..The finding of gender differences deserves further research to answer definitively the important question of gender susceptibility to adverse cognitive effects from β-amyloid...
  24. ncbi Relationship between atrophy and beta-amyloid deposition in Alzheimer disease
    Gael Chetelat
    Department of Nuclear Medicine and Center for PET, Austin Health, 145 Studley Road, Heidelberg, Victoria 3084, Australia
    Ann Neurol 67:317-24. 2010
    ..The present study aims to assess this relationship...
  25. doi Independent contribution of temporal beta-amyloid deposition to memory decline in the pre-dementia phase of Alzheimer's disease
    Gael Chetelat
    Department of Nuclear Medicine and Centre for PET, Austin Health, 145 Studley Road, Heidelberg, VIC 3084, Australia
    Brain 134:798-807. 2011
    ....
  26. doi In vitro characterisation of BF227 binding to alpha-synuclein/Lewy bodies
    Michelle T Fodero-Tavoletti
    Department of Pathology, The University of Melbourne, Vic, Australia
    Eur J Pharmacol 617:54-8. 2009
    ..This study suggests that [(18)F]-BF227 is not Abeta-selective. Evaluation of BF227 as a potential biomarker for Parkinson's disease is warranted...
  27. doi Stronger effect of amyloid load than APOE genotype on cognitive decline in healthy older adults
    Yen Ying Lim
    Mental Health Research Institute, The University of Melbourne, Parkville, Australia
    Neurology 79:1645-52. 2012
    ..Although the APOE ε4 allele is associated with more rapid decline in memory in healthy older adults, the significance of elevated cerebral β-amyloid (Aβ) load for longitudinal changes in cognition is unclear...
  28. doi Increasing the predictive accuracy of amyloid-β blood-borne biomarkers in Alzheimer's disease
    Andrew D Watt
    Department of Pathology, The University of Melbourne, Parkville, Melbourne, Victoria, Australia
    J Alzheimers Dis 24:47-59. 2011
    ..Furthermore, the findings indicate that the incorporation of non-amyloid markers into predictive models, function to increase the accuracy of the diagnostic potential of Aβ...
  29. ncbi Imaging of amyloid beta in Alzheimer's disease with 18F-BAY94-9172, a novel PET tracer: proof of mechanism
    Christopher C Rowe
    Department of Nuclear Medicine and Centre for PET, Austin Health, Heidelberg, Victoria, Australia
    Lancet Neurol 7:129-35. 2008
    ..18)F-BAY94-9172 is an Abeta ligand that, due to the half-life of (18)F, is suitable for clinical use. We thus studied the effectiveness of this ligand in identifying patients with AD...
  30. doi Addressing population aging and Alzheimer's disease through the Australian imaging biomarkers and lifestyle study: collaboration with the Alzheimer's Disease Neuroimaging Initiative
    Kathryn A Ellis
    Department of Psychiatry, Academic Unit for Psychiatry of Old Age, University of Melbourne, Kew, Victoria, Australia
    Alzheimers Dement 6:291-6. 2010
    ..Cross-sectional analysis of baseline data is revealing links between cognition, brain amyloid burden, structural brain changes, biomarkers, and lifestyle...
  31. doi In vivo measurement of vesicular monoamine transporter type 2 density in Parkinson disease with (18)F-AV-133
    Nobuyuki Okamura
    Department of Nuclear Medicine and Centre for PET, Austin Health, Victoria, Australia
    J Nucl Med 51:223-8. 2010
    ..PET provides a noninvasive means to evaluate the functional integrity of the presynaptic monoaminergic system in the living human brain...
  32. doi Cognitive consequences of high Aβ amyloid in mild cognitive impairment and healthy older adults: implications for early detection of Alzheimer's disease
    Yen Ying Lim
    Mental Health Research Institute, The University of Melbourne, Parkville, Victoria, Australia
    Neuropsychology 27:322-32. 2013
    ..We aimed to determine the extent to which high Aβ amyloid influenced cognitive function in healthy older adults and adults with MCI...
  33. doi Three-month stability of the CogState brief battery in healthy older adults, mild cognitive impairment, and Alzheimer's disease: results from the Australian Imaging, Biomarkers, and Lifestyle-rate of change substudy (AIBL-ROCS)
    Yen Ying Lim
    Mental Health Research Institute, The University of Melbourne, Parkville, Victoria, Australia
    Arch Clin Neuropsychol 28:320-30. 2013
    ..This may potentially be used to inform future estimates of cognitive change in clinical trials...
  34. ncbi Longitudinal analysis of serum copper and ceruloplasmin in Alzheimer's disease
    Alan Rembach
    The Mental Health Research Institute, The University of Melbourne, Vic, Australia
    J Alzheimers Dis 34:171-82. 2013
    ..The aim of this study was to determine the diagnostic value of serum copper, CP, and non-CP copper levels in a large cohort of AD subjects...
  35. doi Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging
    Christopher C Rowe
    Austin Health, Department of Nuclear Medicine and Centre for PET, Heidelberg, Victoria, Australia
    Neurobiol Aging 31:1275-83. 2010
    ....
  36. doi Cognitive decline in adults with amnestic mild cognitive impairment and high amyloid-β: prodromal Alzheimer's disease?
    Yen Ying Lim
    Mental Health Research Institute, The University of Melbourne, Parkville, Vic, Australia
    J Alzheimers Dis 33:1167-76. 2013
    ....
  37. ncbi Beta-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease
    Kerryn E Pike
    School of Psychology, Psychiatry and Psychological Medicine, Monash University, Melbourne, Australia
    Brain 130:2837-44. 2007
    ..The data also suggests that early intervention trials for AD targeted to non-demented individuals with cerebral Abeta deposition are warranted...
  38. doi Olfactory deficits and amyloid-β burden in Alzheimer's disease, mild cognitive impairment, and healthy aging: a PiB PET study
    Alex Bahar-Fuchs
    Department of Nuclear Medicine and Centre for PET, Austin Health, Heidelberg, Victoria, Australia
    J Alzheimers Dis 22:1081-7. 2010
    ..We conclude that AD-related olfactory identification deficits are not directly related to Aβ burden...
  39. doi Larger temporal volume in elderly with high versus low beta-amyloid deposition
    Gael Chetelat
    Department of Nuclear Medicine and Centre for PET, Austin Health, 145 Studley Road, Heidelberg, VIC 3084, Australia
    Brain 133:3349-58. 2010
    ..Our complementary analyses tend to support the latter hypotheses. Overall, our findings suggest that the deleterious effects of β-amyloid on cognition may be delayed in those subjects with larger brain (temporal) volume...
  40. doi Characterization of PiB binding to white matter in Alzheimer disease and other dementias
    Michelle T Fodero-Tavoletti
    Department of Pathology, University of Melbourne, and Department of Nuclear Medicine, Centre for PET, Austin Hospital, Heidelberg, Victoria, Australia
    J Nucl Med 50:198-204. 2009
    ..Although the specificity of PiB for Abeta plaques in gray matter has been well described, the nature of PiB binding to white matter remains unclear. In this study, we characterized the binding of PiB to human white matter homogenates...
  41. ncbi Bis(thiosemicarbazonato) Cu-64 complexes for positron emission tomography imaging of Alzheimer's disease
    Michelle T Fodero-Tavoletti
    Department of Pathology, University of Melbourne, Melbourne, Victoria, Australia
    J Alzheimers Dis 20:49-55. 2010
    ..This approach has the potential to offer complementary information to other diagnostic procedures that elucidate plaque burden...
  42. doi Rapid decline in episodic memory in healthy older adults with high amyloid-β
    Yen Ying Lim
    Mental Health Research Institute, The University of Melbourne, Parkville, Vic, Australia
    J Alzheimers Dis 33:675-9. 2013
    ..High Aβ was associated with greater decline in episodic memory measures over 6 months in healthy older adults...
  43. ncbi A copper radiopharmaceutical for diagnostic imaging of Alzheimer's disease: a bis(thiosemicarbazonato)copper(II) complex that binds to amyloid-beta plaques
    SinChun Lim
    School of Chemistry, The University of Melbourne, Parkville, Victoria, Australia 3010
    Chem Commun (Camb) 46:5437-9. 2010
    ..The complex has the potential to be of use as a copper-64 radiopharmaceutical to assist in the diagnosis of Alzheimer's disease by positron emission tomography...
  44. ncbi Relationship between memory performance and β-amyloid deposition at different stages of Alzheimer's disease
    Gael Chetelat
    Department of Nuclear Medicine and Centre for PET, Austin Health, Heidelberg, Vic, Australia
    Neurodegener Dis 10:141-4. 2012
    ..The development of Aβ ligands for in vivo PET imaging has greatly facilitated the assessment of this question...
  45. ncbi Visual assessment versus quantitative assessment of 11C-PIB PET and 18F-FDG PET for detection of Alzheimer's disease
    Steven Ng
    Department of Nuclear Medicine, Centre for PET, Austin Health, Heidelberg, Victoria, Australia
    J Nucl Med 48:547-52. 2007
    ..The aim of this study was to explore the clinical potential of Abeta imaging for the diagnosis of AD by comparison of the accuracy of visual reading of (11)C-PIB images with quantitative analysis and (18)F-FDG...
  46. doi Investigation of matrix metalloproteinases, MMP-2 and MMP-9, in plasma reveals a decrease of MMP-2 in Alzheimer's disease
    Nastasia K H Lim
    Department of Pathology, The University of Melbourne, Parkville VIC, Australia
    J Alzheimers Dis 26:779-86. 2011
    ..16, p < 0.05), but there was no association with PiB. This is the first report of a change in MMP-2 activity in AD plasma and these findings may provide some insight into AD pathogenesis...
  47. doi 18F-THK523: a novel in vivo tau imaging ligand for Alzheimer's disease
    Michelle T Fodero-Tavoletti
    Department of Pathology, The University of Melbourne, Victoria, 3010, Australia
    Brain 134:1089-100. 2011
    ..The preclinical examination of THK523 has demonstrated its high affinity and selectivity for tau pathology both in vitro and in vivo, indicating that (18)F-THK523 fulfils ligand criteria for human imaging trials...
  48. ncbi Advances in structural and molecular neuroimaging in Alzheimer's disease
    Kathryn A Ellis
    Academic Unit for Psychiatry of Old Age, Department of Psychiatry, University of Melbourne, Melbourne, Vic, Australia
    Med J Aust 194:S20-3. 2011
    ....
  49. ncbi Evaluating atypical dementia syndromes using positron emission tomography with carbon 11 labeled Pittsburgh Compound B
    Steven Y Ng
    Department of Nuclear Medicine and Centre for Positron Emission Tomography, Austin Health, Melbourne, Australia
    Arch Neurol 64:1140-4. 2007
    ..However, patients presenting with atypical or focal clinical symptoms such as language or visuospatial dysfunction often pose a diagnostic challenge...
  50. ncbi The association of Aβ amyloid and composite cognitive measures in healthy older adults and MCI
    Karra D Harrington
    Mental Health Research Institute, The University of Melbourne, Parkville, Victoria, Australia
    Int Psychogeriatr 25:1667-77. 2013
    ..This study aimed to describe the nature and magnitude of the relationship between Aβ amyloid and cognitive performance of individuals without dementia...
  51. pmc Incidence of cerebral microbleeds in preclinical Alzheimer disease
    Paul A Yates
    From the Department of Nuclear Medicine and Centre for PET P A Y, V L V, C C R, Austin Health, Heidelberg The University of Melbourne P A Y, P M D, C S, C C R, Parkville Department of Radiology P M D, P M P, C S, Royal Melbourne Hospital, Parkville National Ageing Research Institute D A, Parkville CSIRO Preventative Health Flagship O S, Parkville Florey Institute of Neuroscience and Mental Health K A E, C L M, V L V, The University of Melbourne, Parkville Academic Unit for Psychiatry of Old Age K A E, D A, Department of Psychiatry, The University of Melbourne, Kew, Victoria Centre of Excellence for Alzheimer s Disease Research and Care R N M, School of Exercise, Biomedical and Health Sciences, Edith Cowan University, Australia
    Neurology 82:1266-73. 2014
    ..We sought to determine the incidence and associations of lobar microbleeds (LMBs) in a longitudinal cohort with (11)C-Pittsburgh compound B (PiB) PET imaging...
  52. pmc Effect of BDNF Val66Met on memory decline and hippocampal atrophy in prodromal Alzheimer's disease: a preliminary study
    Yen Ying Lim
    Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Parkville, Victoria, Australia
    PLoS ONE 9:e86498. 2014
    ..We aimed to determine whether BDNF Val66Met polymorphism influences changes in memory performance, hippocampal volume, and Aβ accumulation in adults with amnestic mild cognitive impairment (aMCI) and high Aβ...
  53. doi Subacute ischemic stroke is associated with focal 11C PiB positron emission tomography retention but not with global neocortical Aβ deposition
    John V Ly
    University of Melbourne, Carlton South, Australia
    Stroke 43:1341-6. 2012
    ..Specifically, we hypothesized that patients with recent ischemic stroke have higher local and neocortical PiB positron emission tomography retention and that this may be associated with major vascular risk factors...
  54. doi The 18F-FDG PET cingulate island sign and comparison to 123I-beta-CIT SPECT for diagnosis of dementia with Lewy bodies
    Seok Ming Lim
    Department of Nuclear Medicine and Centre for PET, Austin Health, Victoria, Australia
    J Nucl Med 50:1638-45. 2009
    ....
  55. ncbi Rates of diagnostic transition and cognitive change at 18-month follow-up among 1,112 participants in the Australian Imaging, Biomarkers and Lifestyle Flagship Study of Ageing (AIBL)
    Kathryn A Ellis
    Academic Unit for Psychiatry of Old Age, Department of Psychiatry, University of Melbourne St Vincent s Aged Psychiatry Service, St George s Hospital, Kew, Victoria, Australia
    Int Psychogeriatr 26:543-54. 2014
    ..The first aim was to compute rates of transition from HC to MCI, and MCI to AD. The second aim was to characterize the cognitive profiles of individuals who transitioned to a more severe disease stage compared with those who did not...
  56. doi Head-to-head comparison of 11C-PiB and 18F-AZD4694 (NAV4694) for β-amyloid imaging in aging and dementia
    Christopher C Rowe
    Department of Nuclear Medicine and Centre for PET, Austin Health, Heidelberg, Victoria, Australia
    J Nucl Med 54:880-6. 2013
    ..We compared the cortical and white matter binding of a new (18)F-labeled Aβ tracer, (18)F-AZD4694 (recently renamed NAV4694), with (11)C-PiB in the same subjects...
  57. doi Amyloid imaging with PET in early Alzheimer disease diagnosis
    Christopher C Rowe
    Department of Nuclear Medicine, Centre for PET, University of Melbourne, Austin Health, Heidelberg, Victoria 3084, Australia
    Med Clin North Am 97:377-98. 2013
    ..Longitudinal observations are required to elucidate the role of Aβ deposition in the course of Alzheimer disease and provide information needed to fully use the prognostic power of this investigation...
  58. doi In vitro characterization of [18F]-florbetaben, an Aβ imaging radiotracer
    Michelle T Fodero-Tavoletti
    Department of Pathology, The University of Melbourne, Victoria 3010, Australia
    Nucl Med Biol 39:1042-8. 2012
    ..The objective of this study was to determine whether Florbetaben selectively binds to Aβ plaques in postmortem tissue specimens containing mixed pathological hallmarks (i.e., tau and α-synuclein aggregates)...
  59. doi Homocysteine, vitamin B12, and folic acid levels in Alzheimer's disease, mild cognitive impairment, and healthy elderly: baseline characteristics in subjects of the Australian Imaging Biomarker Lifestyle study
    Noel G Faux
    The Mental Health Research Institute, The University of Melbourne, Parkville, Vic, Australia
    J Alzheimers Dis 27:909-22. 2011
    ..These findings underscore the association of plasma homocysteine with cognitive deterioration, although not unique to AD, and identified an unexpected abnormality of red cell folate...
  60. ncbi In vitro characterization of Pittsburgh compound-B binding to Lewy bodies
    Michelle T Fodero-Tavoletti
    Department of Pathology, The University of Melbourne, Melbourne, Victoria 3010, Australia
    J Neurosci 27:10365-71. 2007
    ..These studies indicate that PIB retention observed within the cortical gray matter regions of DLB subjects in [11C]-PIB PET studies is largely attributable to PIB binding to Abeta plaques and not Lewy bodies...
  61. ncbi Amyloid imaging in Alzheimer's disease and other dementias
    Michelle T Fodero-Tavoletti
    Department of Pathology, The University of Melbourne, Melbourne, Victoria, 3010, Australia
    Brain Imaging Behav 3:246-61. 2009
    ....
  62. ncbi Molecular mechanisms for Alzheimer's disease: implications for neuroimaging and therapeutics
    Colin L Masters
    Department of Pathology, The University of Melbourne, Vic, Australia
    J Neurochem 97:1700-25. 2006
    ....
  63. ncbi Anxiety symptoms, cerebral amyloid burden and memory decline in healthy older adults without dementia: 3-year prospective cohort study
    Robert H Pietrzak
    Robert H Pietrzak, PhD, MPH, J Cobb Scott, PhD, United States Department of Veterans Affairs National Center for Posttraumatic Stress Disorder, Clinical Neurosciences Division, VA Connecticut Healthcare System, West Haven and Department of Psychiatry, Yale School of Medicine, New Haven, Connecticut, USA Alexander Neumeister, MD, Departments of Psychiatry and Radiology, New York University School of Medicine, New York, USA Yen Ying Lim, PhD, The Florey Institute of Neuroscience and Mental Health, Parkville, Victoria, Australia David Ames, MD, Academic Unit for Psychiatry of Old Age, St Vincent s Health, Department of Psychiatry, The University of Melbourne, Kew and National Ageing Research Institute, Parkville, Victoria, Australia Kathryn A Ellis, PhD, The Florey Institute of Neuroscience and Mental Health, Parkville, Academic Unit for Psychiatry of Old Age, St Vincent s Health, Department of Psychiatry, The University of Melbourne, Kew and National Ageing Research Institute, Parkville, Victoria, Pest Infestation Laboratory
    Br J Psychiatry 204:400-1. 2014
    ..These findings suggest that interventions to mitigate anxiety symptoms may help delay memory decline in otherwise healthy older adults with elevated beta-amyloid. ..
  64. doi Plasma amyloid-β levels are significantly associated with a transition toward Alzheimer's disease as measured by cognitive decline and change in neocortical amyloid burden
    Alan Rembach
    The Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Vic, Australia
    J Alzheimers Dis 40:95-104. 2014
    ..We evaluated the utility of longitudinal measures of plasma amyloid-β (Aβ) as a means to identify pre-symptomatic cognitive decline in Alzheimer's disease (AD) when coupled to neuroimaging and neuropsychological parameters...
  65. doi Variability in blood-based amyloid-beta assays: the need for consensus on pre-analytical processing
    Andrew D Watt
    Department of Pathology, The University of Melbourne, Parkville, Melbourne, Vic, Australia
    J Alzheimers Dis 30:323-36. 2012
    ..This review highlights the current shortcomings in methodological reporting and recommends a standardized blood collection methodology based on the limited consensus of the reviewed articles...
  66. doi Episodic memory decline predicts cortical amyloid status in community-dwelling older adults
    David G Darby
    CogState Ltd, Melbourne, Australia
    J Alzheimers Dis 27:627-37. 2011
    ..This approach may help detect early prodromal AD pathology in wider-scale community screening programs...
  67. ncbi Simplified quantification of nicotinic receptors with 2[18F]F-A-85380 PET
    Sascha Mitkovski
    Department of Nuclear Medicine and Centre for PET, Austin Hospital, Victoria 3084, Melbourne, Australia
    Nucl Med Biol 32:585-91. 2005
    ..We sought to evaluate a minimally invasive method for quantification of nAChR distribution in the normal human brain, suitable for routine clinical application, using 2[(18)F]F-A-85380 and positron emission tomography (PET)...
  68. doi Amyloid-β: the seeds of darkness
    Michelle T Fodero-Tavoletti
    Department of Pathology, Bio21 Molecular and Biotechnology Institute, University of Melbourne, Parkville, Victoria 3010, Australia
    Int J Biochem Cell Biol 43:1247-51. 2011
    ..Although Alzheimer's disease remains incurable, improvements to Aβ immunotherapies and strategies to target Aβ continue to evolve, with the reliance upon Aβ imaging to shed light on the outcome of therapeutics proving very useful...
  69. doi Blood-borne amyloid-beta dimer correlates with clinical markers of Alzheimer's disease
    Victor L Villemagne
    Mental Health Research Institute, The University of Melbourne, Parkville, Melbourne, Victoria 3052, Australia
    J Neurosci 30:6315-22. 2010
    ..These results indicate that fundamental biochemical events relevant to AD can be monitored in blood, and that the species detected may be useful clinical biomarkers for AD...
  70. doi Oligomers, fact or artefact? SDS-PAGE induces dimerization of β-amyloid in human brain samples
    Andrew D Watt
    Mental Health Research Institute, The University of Melbourne, Parkville, Melbourne, VIC 3052, Australia
    Acta Neuropathol 125:549-64. 2013
    ..The findings that SDS promotes Aβ dimerization have significant implications for the putative role of low-order oligomers in AD pathogenesis and draw into question the utility of oligomeric Aβ as a therapeutic target...
  71. ncbi Imaginem oblivionis: the prospects of neuroimaging for early detection of Alzheimer's disease
    Victor L Villemagne
    Department of Nuclear Medicine, Centre for PET, Austin Hospital, Melbourne, Vic, Australia
    J Clin Neurosci 12:221-30. 2005
    ..From this, the prospect of specific preclinical diagnosis arises, possibly in conjunction with other related A beta biomarkers in plasma and CSF...
  72. doi Cerebral β-amyloid detected by Pittsburgh compound B positron emission topography predisposes to recombinant tissue plasminogen activator-related hemorrhage
    John V Ly
    National Stroke Research Institute, Austin Health, University of Melbourne, Heidelberg Heights, Australia
    Ann Neurol 68:959-62. 2010
    ..This finding may provide an impetus for the development of a more practical rapid pretreatment screening technique...
  73. ncbi Imaging beta-amyloid burden in aging and dementia
    C C Rowe
    Department of Nuclear Medicine, Centre for PET, Austin Health, Heidelberg, Victoria, Australia
    Neurology 68:1718-25. 2007
    ..To compare brain beta-amyloid (Abeta) burden measured with [(11)C]Pittsburgh Compound B (PIB) PET in normal aging, Alzheimer disease (AD), and other dementias...
  74. ncbi Radioiodinated clioquinol as a biomarker for beta-amyloid: Zn complexes in Alzheimer's disease
    Carlos Opazo
    Oxidation Disorders Laboratory, Mental Health Research Institute of Victoria, and Department of Pathology, The University of Melbourne, Parkville, Victoria, Australia
    Aging Cell 5:69-79. 2006
    ..These data support metallated Abeta species as the neuropharmacological target of CQ and indicate that this drug class may have potential as in vivo imaging agents for Alzheimer neuropathology...
  75. doi Brain amyloid imaging
    Christopher C Rowe
    Department of Nuclear Medicine and Centre for PET, Austin Health, Melbourne, Australia
    J Nucl Med 52:1733-40. 2011
    ..This article will provide nuclear medicine physicians with the background knowledge required for understanding this emerging investigation, including its appropriate use, and prepare them for practical training in scan interpretation...
  76. ncbi Relationship between nicotinic receptors and cognitive function in early Alzheimer's disease: a 2-[18F]fluoro-A-85380 PET study
    J R Ellis
    Department of Nuclear Medicine and Centre for PET, Austin Hospital, 145 Studley Road, Heidelberg, Victoria 3084, Australia
    Neurobiol Learn Mem 90:404-12. 2008
    ..It is possible that while the clinical 2-FA PET method described here may be insensitive in detecting changes in early AD, such changes may be detected in more advanced stages of the illness...
  77. doi Galantamine-induced improvements in cognitive function are not related to alterations in alpha(4)beta (2) nicotinic receptors in early Alzheimer's disease as measured in vivo by 2-[18F]fluoro-A-85380 PET
    J R Ellis
    School of Psychology, Psychiatry, and Psychological Medicine, Monash University, Melbourne, Victoria, Australia
    Psychopharmacology (Berl) 202:79-91. 2009
    ..e., galantamine) that potentiate cholinergic neurotransmission improve cognitive function in Alzheimer's disease (AD); however, the relationship between these effects and associated changes in nAChRs are yet to be established in vivo...
  78. doi The relationship between nicotinic receptors and cognitive functioning in healthy aging: An in vivo positron emission tomography (PET) study with 2-[(18)F]fluoro-A-85380
    J R Ellis
    Monash University, Victoria, Australia
    Synapse 63:752-63. 2009
    ..However, this approach may be appropriate for use in pathologies considered to undergo extensive nAChR loss such as Alzheimer's disease and Parkinson's disease...
  79. doi Brain amyloid imaging
    Christopher C Rowe
    Department of Nuclear Medicine and Centre for PET, Austin Health, Melbourne, Australia
    J Nucl Med Technol 41:11-8. 2013
    ..This article will provide nuclear medicine physicians with the background knowledge required for understanding this emerging investigation, including its appropriate use, and prepare them for practical training in scan interpretation...
  80. doi Metals, membranes, and amyloid-β oligomers: key pieces in the Alzheimer's disease puzzle?
    Andrew D Watt
    Department of Pathology, The University of Melbourne, Parkville, Melbourne, Vic, Australia
    J Alzheimers Dis 33:S283-93. 2013
    ..This review focuses on some of the recent work we have conducted toward elucidating the role of Aβ in AD...
  81. doi 11C-PIB binding is increased in patients with cerebral amyloid angiopathy-related hemorrhage
    J V Ly
    National Stroke Research Institute, Level 1, Neurosciences Building, Austin Health, University of Melbourne, 300 Waterdale Rd, Heidelberg Heights, Victoria 3081, Australia
    Neurology 74:487-93. 2010
    ..We hypothesized that patients with a clinical diagnosis of CAA-related hemorrhage (CAAH) have increased (11)C-PIB uptake and that the pattern differs from Alzheimer disease (AD)...
  82. ncbi Brain glucose metabolism in Rett Syndrome
    Patricia M Villemagne
    Department of Radiology, Johns Hopkins Medical Institutions, Baltimore, Maryland 21287 0807, USA
    Pediatr Neurol 27:117-22. 2002
    ..This pattern differs from those described in Down syndrome, autism, and Alzheimer's disease...
  83. ncbi The quest for Eldorado: development of radioligands for in vivo imaging of nicotinic acetylcholine receptors in human brain
    Andrew G Horti
    Division of Nuclear Medicine, Department of Radiology, Johns Hopkins Medicine, Baltimore, MD USA
    Curr Pharm Des 12:3877-900. 2006
    ..In particular, new PET nAChR radioligands will be examined that either present faster brain kinetics allowing simple and reliable quantification approaches or higher binding potentials suitable for the evaluation of extrathalamic nAChR...
  84. ncbi Sequential H(2)(15)O PET studies in baboons: before and after amphetamine
    Julie C Price
    Department of Radiology, University of Pittsburgh School of Medicine, Pennsylvania 15213, USA
    J Nucl Med 43:1090-100. 2002
    ..A common assumption in bolus injection PET studies of this type is that cerebral blood flow (CBF) does not vary during the scan. The goal of this work was to examine the effect of AMPH administration on sequential PET measures of CBF...
  85. ncbi MR atlas of the baboon brain for functional neuroimaging
    Phil J Greer
    University of Pittsburgh PET Facility, Pittsburgh, PA 15213 2582, USA
    Brain Res Bull 58:429-38. 2002
    ..Overall, the digital MR-based atlas allowed for automatic co-registration, proved useful across a range of PET Studies, and is accessible electronically via the Internet...